Leveraging reimbursement strategies to guide value-based adoption and utilization of medical AI

With the increasing number of FDA-approved artificial intelligence (AI) systems, the financing of these technologies has become a primary gatekeeper to mass clinical adoption. Reimbursement models adapted for current payment schemes, including per-use rates, are feasible for early AI products. Alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Venkatesh, Kaushik P., Raza, Marium M., Diao, James A., Kvedar, Joseph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364287/
https://www.ncbi.nlm.nih.gov/pubmed/35948612
http://dx.doi.org/10.1038/s41746-022-00662-1
Descripción
Sumario:With the increasing number of FDA-approved artificial intelligence (AI) systems, the financing of these technologies has become a primary gatekeeper to mass clinical adoption. Reimbursement models adapted for current payment schemes, including per-use rates, are feasible for early AI products. Alternative and complementary models may offer future payment options for value-based AI. A successful reimbursement strategy will align interests across stakeholders to guide value-based and cost-effective improvements to care.

Ejemplares similares